Merck & Co., Inc. MRK
133.72 USD +0.91 (+0.69%)
Regular-session close
133.76 +0.04 +0.03%
After hours · Nov 20, 7:55 PM ET
133.11 Day range 137.17
94.97 52-week range 156.45
- YTD
- +27.04%
- 1 year
- +40.80%
News
defenseworld.net 11,187 Merck & Co., Inc. $MRK Shares Purchased by Allianz SE Allianz SE boosted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 10.0% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange…
defenseworld.net Merck & Co., Inc. $MRK Stake Reduced by Barrow Hanley Mewhinney & Strauss LLC Barrow Hanley Mewhinney and Strauss LLC reduced its stake in Merck and Co., Inc. (NYSE: MRK) by 69.8% during the third quarter, according to its most recent Form 13F filing with the Securities and…
fool.com 1 High-Flying Stock to Buy Hand Over Fist if the Stock Market Crashes Moderna's cancer vaccine data were historic, but the stock prices in a flawless future.
benzinga.com Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer Merck & Co. Inc. (NYSE:MRK) on Friday announced that its pivotal Phase 3 TroFuse-015 trial met its primary endpoint of overall survival (OS).
benzinga.com Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric Cancer Merck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.
zacks.com HALO Faces Legal Setback in Germany Over MRK's Keytruda SC, Stock Down Halozyme faces a legal setback in Germany as a court overturns an injunction against Merck's Keytruda SC, prompting a new patent lawsuit.
benzinga.com Defensives Lead Sectors Friday As Growth Trails Six sectors are higher and five are lower in Friday's regular session, with defensive sectors holding two of the top three positions alongside Energy. The leaders are separated rather than clustered,…
reuters.com Merck's drug prolongs survival in advanced stomach, esophageal cancers in trial Merck's drug prolongs survival in advanced stomach, esophageal cancers in trialbenzinga.com Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal Adenocarcinoma Sac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of…
benzinga.com Halozyme Stock Slides, European Patent Fight With Merck Spurs Fresh Pressure Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares are trading lower on Thursday as investors digest an update on its European patent fight with Merck, while risk appetite is already soft with the S&P…
benzinga.com AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiples AstraZeneca commits $200 million to Tempus AI in a master services agreement renewal through 2031, while William Blair maintains a Market Perform rating.
benzinga.com Technology Only Sector Higher Thursday As Defensives Fall Thursday's regular session has one sector higher and 10 lower, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with Technology sitting…
zacks.com Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.benzinga.com Halozyme Therapeutics Says Disappointed That Higher Regional Court Overturned The Preliminary Injunction Ordering Merck To Refrain From Distributing And Offering Keytruda In Germany Halozyme Therapeutics, Inc. (NASDAQ:HALO) (Halozyme), today provided an update on the German preliminary injunction hearing that overturned the decision issued in December 2025, ordering Merck to…
seekingalpha.com Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript Merck & Co., Inc. (MRK) Presents at Jefferies London Healthcare Conference Transcript
marketbeat.com Merck & Co. Eyes Kidney Cancer Data as Vaccine Research Expands Beyond Melanoma Merck & Co., Inc. NYSE: MRK is studying how its experimental personalized cancer vaccine might work across different tumor types, with kidney cancer data expected to help determine whether the…
benzinga.com Immutep Reports 81.1% Disease-Free Survival Rate in Soft Tissue Sarcoma Trial Immutep posts an 81.1% 12-month disease-free survival rate in its Phase 2 soft tissue sarcoma study and plans a new trial in 2027.
businesswire.com Merck and Isomorphic Labs Enter Strategic Research Collaboration RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Isomorphic Labs, an AI-first drug design and development company, today announced a…
defenseworld.net Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $8,611,961.85 in Stock Merck and Co., Inc. (NYSE: MRK - Get Free Report) EVP Richard Deluca sold 58,185 shares of the business's stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an…
zacks.com Bristol Myers vs. Merck: Which Big Pharma Stock Is the Better Buy? MRK emerges as the stronger investment choice over BMY, backed by superior stock performance, oncology leadership, pipeline expansion and diversified growth drivers.
zacks.com Merck Ends Nemtabrutinib Development: What's Next for Its Pipeline? MRK ends nemtabrutinib development after phase III safety concerns, shifting focus to its expanding pipeline assets.
benzinga.com Growth Leads Sectors In Wednesday Trading As Cyclicals Trail Five sectors are trading higher and six are lower in Wednesday's regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single…
benzinga.com Merck Pulls Plug On Acquired Drug after Safety Review Merck discontinues its nemtabrutinib and BELLWAVE leukemia clinical program after an external review found risks may outweigh benefits.
businesswire.com Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director RAHWAY, N.J.--(BUSINESS WIRE)--Thomas H. Glocer to Retire From Merck Board of Directors in May 2027; Douglas M. Baker, Jr. Appointed Independent Lead Director.
reuters.com Merck stops trials of blood cancer drug after risk assessment Merck stops trials of blood cancer drug after risk assessment
businesswire.com Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development program…
benzinga.com Eli Lilly Short Interest Rises, Remains Below August Peak Eli Lilly and Co. (NYSE:LLY) short sellers added to their positions, with the latest report following the company’s Q3 2026 earnings release.Short interest rose 3.64% to 7.21 million shares as of the…
businesswire.com Merck Announces First-Quarter 2027 Dividend RAHWAY, N.J.--(BUSINESS WIRE)--Merck Announces First-Quarter 2027 Dividend.
247wallst.com Forget SCHD: 4 Dividend Stocks Retirees Should Own Instead SCHD anchors countless retirement portfolios, yet its payout barely budged this past year while living costs kept climbing. Four household-name stocks promise faster raises, but each carries a risk…benzinga.com Reported November 16, Roche Receives FDA Approval For Wiserdley In Combination With Everolimus For Breast Cancer Treatment Wilserdly is the first and only next-generation all-oral SERD combination to significantly outperform standard endocrine combination in a post-CDK4/6 inhibitor setting in a head-to-head phase III…
defenseworld.net Merck & Co., Inc. (NYSE:MRK) Share Price Breaks Below Fifty Day Moving Average Following Insider Selling Merck and Co., Inc. (NYSE: MRK - Get Free Report)'s share price crossed below its fifty day moving average during trading on Monday following insider selling activity. The stock has a fifty day…
fool.com Is Merck's Stock Still a Good Buy at $150? Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on…
247wallst.com How Much Does a 56-Year-Old Need Invested to Replace a $145,000 Salary With Dividends? Replacing a paycheck with dividends sounds simple until you see the price tag at different yields. Then a few overlooked details, from taxes to payroll deductions, quietly shrink the target, and one…
247wallst.com Moderna Is Up Over 600% This Year. Here’s What Jim Cramer Learned in His Exclusive One melanoma headline turned a $63 stock into a market darling, and Moderna's CEO just told Jim Cramer when patients could get the shot. Does the price already bake in the cancer breakthrough, or is…
benzinga.com Meet Wall Street’s New Dividend King: SCHD’s $27.5B Inflow Surge Signals Shift Away from AI Schwab U.S. Dividend Equity ETF (SCHD) is now America's largest dividend ETF, overtaking VIG. Is Wall Street changing its mind on AI?
seekingalpha.com Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November I expect Nike (NKE) to raise its dividend 1.2–2.4%, as weak sales, flat EPS and a payout ratio around 80% constrain growth. Matthews International (MATW) risks a dividend cut; Hormel (HRL) faces an…
defenseworld.net Merck & Co., Inc. $MRK Stock: Aberdeen Group plc Decreases Stake Aberdeen Group plc cut its holdings in Merck and Co., Inc. (NYSE: MRK) by 87.4% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission.…benzinga.com EMA’s CHMP Adopts Positive Opinion Recommending Approval Of Merck’s WELIREG Plus Lenvatinib For Treatment Of Advanced Renal Cell Carcinoma With Clear Cell Component; Final Decision Expected In Next Two Months Opinion granted based on positive progression-free survival results from the Phase 3 LITESPARK-011 trialIf approved, this regimen will be the first and only approved combination of a HIF-2α inhibitor…
benzinga.com FDA Reportedly Shelves Fast-Track Drug Review Pilot Program During Leadership Vacuum: Report The FDA reportedly shelves its fast-track drug voucher pilot amid internal chaos, returning review oversight to career scientists.
benzinga.com Moderna Analyst Day: Details Strategic Shift Toward Oncology and Enhanced Production Capabilities Moderna raises its 2026 revenue forecast to 15%-25% and accelerates oncology investments, expanding its mRNA platform into new therapies.
benzinga.com Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep shares rise after reporting promising Phase 2 sarcoma trial results for efti and securing a key U.S. patent valid through 2038.
benzinga.com Cyclicals Lead Sectors In Wednesday Trading As Defensives Trail Five sectors are higher and six are lower in Wednesday's regular session, with cyclical sectors holding two of the top three positions. Technology sits well clear of the rest, separated from the next…
benzinga.com EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat Democrats have two ways to pressure drugmakers. Eli Lilly, Gilead, Merck, Bristol Myers face different levels of Medicare pricing exposure.benzinga.com 'Merck KGaA lands FDA nod for joint tumor drug it licensed from Abbisko'- Endpoints News https://endpoints.news/merck-kgaa-lands-fda-nod-for-joint-tumor-drug-it-licensed-from-abbisko/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
benzinga.com Merck Reports Phase 2b Results For Efinopegdutide In MASH, Meaningful Improvements Were Observed In Liver Fibrosis Without Worsening Of Steatohepatitis, A Key Secondary Histologic Endpoint; Results Presented At The Liver Meeting And Published In The Lancet Efinopegdutide demonstrated a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis versus placebo at 52 weeksMeaningful improvements…
benzinga.com 11 Of 11 Sectors Rise Monday As Growth Leads All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing…
benzinga.com Moderna Stuns Wall Street With Surprise Profit, Raises Outlook Moderna (MRNA) jumps as Q3 earnings swing to a surprise profit of $0.38/share on strong global vaccine sales and cost cuts.
benzinga.com Growth Lead Sectors In Friday Trading As Defensives Trail Seven sectors are higher and four are lower in Friday’s regular session, with growth sectors holding the top three positions. The leaders are separated rather than clustered, with no single gap…benzinga.com Merck Initiates Its ENHANCE-3 Phase 3 Randomized Clinical Trial Evaluating OHTUVAYRE For The Prevention Of Chronic Obstructive Pulmonary Disease Phase 3 randomized clinical trial evaluating OHTUVAYRE (ensifentrine) for the prevention of chronic obstructive pulmonary disease (COPD) exacerbations in adult patients receiving standard of care…
benzinga.com Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155 Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.
